OpGen (NASDAQ:OPGN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Friday, February 16th.
According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
Other equities research analysts have also issued reports about the company. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of OpGen in a research note on Wednesday, November 8th. ValuEngine raised OpGen from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
An institutional investor recently raised its position in OpGen stock. Vanguard Group Inc. raised its position in shares of OpGen Inc (NASDAQ:OPGN) by 1.6% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 342,860 shares of the medical research company’s stock after purchasing an additional 5,500 shares during the period. Vanguard Group Inc. owned about 1.25% of OpGen worth $219,000 as of its most recent filing with the Securities & Exchange Commission.
OpGen Company Profile
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.